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Abstract
Background: Apoptosis resistance occurs in various tumors. The anti-apoptotic XIAP protein is
responsible for inhibiting apoptosis by reducing caspase-3 activation. Our aim is to evaluate
whether RNA inhibition against XIAP increases the sensitivity of canine cell-lines for
chemotherapeutics such as TRAIL and doxorubicin. We used small interfering RNA's (siRNA)
directed against XIAP in three cell-lines derived from bile-duct epithelia (BDE), mammary
carcinoma (P114), and osteosarcoma (D17). These cell-lines represent frequently occurring canine
cancers and are highly comparable to their human counterparts. XIAP down-regulation was
measured by means of quantitative PCR (Q-PCR) and Western blotting. The XIAP depleted cells
were treated with a serial dilution of TRAIL or doxorubicin and compared to mock- and nonsense-
treated controls. Viability was measured with a MTT assay.
Results: All XIAP siRNA treated cell-lines showed a mRNA down-regulation over 80 percent.
Western blot analysis confirmed mRNA measurements. No compensatory effect of IAP family
members was seen in XIAP depleted cells. The sensitivity of XIAP depleted cells for TRAIL was
highest in BDE cells with an increase in the ED50 of 14-fold, compared to mock- and nonsense-
treated controls. The sensitivity of P114 and D17 cell-lines increased six- and five-fold, respectively.
Doxorubicin treatment in XIAP depleted cells increased sensitivity in BDE cells more than eight-
fold, whereas P114 and D17 cell-lines showed an increase in sensitivity of three- and five-fold,
respectively.
Conclusion: XIAP directed siRNA's have a strong sensitizing effect on TRAIL-reduced cell-
viability and a smaller but significant effect with the DNA damaging drug doxorubicin. The increase
in efficacy of chemotherapeutics with XIAP depletion provides the rationale for the use of XIAP
siRNA's in insensitive canine tumors.
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Background
The inhibitor of apoptosis proteins (IAPs) are a family of
structurally related proteins with anti-apoptotic functions.
To date, eight family members have been identified all
carrying a functional baculovirus IAP repeat (BIR)
domain. Members of the IAP family include Survivin, c-
IAP1, c-IAP2, and X-linked inhibitor of apoptosis (XIAP)
which directly bind and inhibit caspases 3, 7, and 9 [1].
XIAP (hILP/MIHA/BIRC4) is the most potent caspase
inhibitor of all family members [2,3]. XAF1 and Smac/
DIABLO regulate XIAP activity, which indicates an impor-
tant function of this protein in maintaining proper apop-
totic functions within the cell.
Apoptosis can be initiated via the intrinsic and/or the
extrinsic pathway [4]. The intrinsic pathway is activated by
intracellular stress such as growth factor withdrawal,
hypoxia, and DNA damage. In this pathway the caspase
cascade is triggered by cytochrome c release from the
mitochondria. On the other hand the extrinsic apoptotic
pathway is triggered by death receptors such as Fas/CD95,
TNF receptor, and the TRAIL receptor. Activation of these
death receptors usually involves caspase 8 activation
which in turn activates effector caspases-3 and -7 [5,6].
Overall, activation of these two pathways is not distinctly
separated as activation of one usually involves the other.
Resistance to apoptosis is a hallmark of various (canine)
cancers [5]. Indeed in various (chemoresitant) tumors the
XIAP protein has been shown to be induced when com-
pared to normal tissue [7-9]. XIAP knock-out mice have
shown that the absence of XIAP does not have a negative
effect on the development of normal tissues [10]. On the
other hand, down-regulation of XIAP with antisense tech-
niques provides antitumor activity in non-small-cell lung
cancer (NSCLC) xenografts [11]. Furthermore studies
with stable expression of short-hairpin RNAs (shRNA)
against XIAP dramatically increased sensitivity of cell-
lines to chemotherapies [12]. Thus, XIAP may represent a
novel and tumor-selective therapeutic target for antican-
cer drug design [13].
In this study we describe the use of siRNA's directed
against XIAP for sensitizing canine cell-lines to TRAIL and
doxorubicin reduced cell-viability. Whereas TRAIL treat-
ment will provide proof of principle, sensitizing tumor
cells to doxorubicin will greatly benefit the use of this
chemotherapeutical in canine tumors. We chose three
cell-lines derived from bile duct-, mammary-, and bone
tumor-tissue which could provide the basis for the thera-
peutic use of siRNA's. Taken together, in order develop
anti-neoplastic therapeutic protocols in dog tumors,
which represent good clinical models [14], we investi-
gated the effect of XIAP siRNA on different apoptotic
agents in canine tumor cell-lines.
Results
Establishing a XIAP down-regulation
Using the Lipofectamine reagent in combination with
magnetic assisted transfection (MATra), we transfected the
cell-lines with siRNA designed from the canine XIAP gene
sequence. The cellular uptake of oligoribonucleotides was
initially determined using fluorescent labeled dsRNA
(Invitrogen). The transfection-efficiency was optimized
and proved to be greater than 95% of the cells as displayed
by green fluorescence FITC labeled siRNA (data not
shown). When treated with the optimal amount of siRNA
(50 nM), the XIAP expression was markedly reduced in all
cell-lines with the highest decrease at 72 hours (Figure 1).
At this time point the mRNA-levels were decreased to 16
percent in BDE cells, 19 percent in D17 cell-lines, and 9
percent in P114 cell-lines lines, compared to control. At
72 hours Western blotting (Figure 1B) yielded a 57 kDa
immunoreactive band of XIAP in the control and non-
sense siRNA transfected samples. Specificity was proven in
controls without first antibody, which was deemed nega-
tive (not shown). Densitometric analysis indicated a
strong reduction of XIAP protein in the XIAP siRNA
treated samples. Cells treated with nonsense siRNA exhib-
ited a similar expression pattern as the control cells (Fig-
ure 1). Viability assays (MTT) indicated an equal cellular
homeostasis in controls towards XIAP down-regulated
cells in all three cell-lines (data not shown).
Treatments
We have measured the effect of XIAP depletion by siRNA-
mediated gene silencing on TRAIL and doxorubicin
induced cell death. As shown in Figure 2, siRNA transfec-
tion increased the sensitivity for TRAIL of all three cell-
lines used. This effect was highest in BDE cells, whereas
P114 cells and D17 were less sensitized by siRNA treat-
ment. XIAP-depleted BDE cells (Figure 2A) showed the
strongest increase in TRAIL-sensitivity; a 14-fold reduction
of the ED50. The P114 and D17 cell-lines showed an
increase in sensitivity of six and five-fold, respectively
(Figures 2B and 2C). For doxorubicin treatment (Figure
3), again the largest increase in sensitivity was seen in the
BDE cells showing a more than eight-fold reduction in the
ED50. The P114 and D17 cell-lines showed an increase in
sensitivity of three and five-fold, respectively (Figures 3B
and 3C).
Gene expression of IAP family members and cellular 
homeostasis
In Figure 4, the effect of XIAP siRNA on XIAP, cIAP-1, and
cIAP-2 mRNA levels is depicted. Results showed that none
of these IAP-family members, other than XIAP, were
affected. XIAP mRNA levels were decreased down to 20
percent in BDE cells, 15 percent in P114 cells, and 20 per-
cent in D17 cells. Nonsense siRNA did induce c-IAP1 lev-
els (165 percent) and Smac/Diablo levels (142 percent) inMolecular Cancer 2006, 5:34 http://www.molecular-cancer.com/content/5/1/34
Page 3 of 10
(page number not for citation purposes)
D17 cells. Measurement of parameters for cellular home-
ostasis revealed an increase in p53 levels in BDE cells and
D17 cells in the nonsense siRNA treated cells. The intro-
duction of siRNA's in P114 cells seemed to induce cell-
cycle and increase viability through inductions in
CCND1, decreases in p27kip, and decreases in caspase-3
mRNA levels in XIAP and nonsense siRNA treated cells.
Discussion
In the present study we observed a strong decrease of
TRAIL- and doxorubicin-induced cell viability with XIAP
siRNA in canine cell-lines. We have used three different
tumor cell-lines in order to be able to conclude about the
general applicability of the outcomes of this study. The
first cell-line studied, a canine liver epithelial cell-line of
biliary origin (BDE) can be considered as an in vitro coun-
terpart of cholangiocarcinoma. The P114 cell-line was
derived from a mammary tumor [15], and the third cell-
line was derived from a canine osteosarcoma (D17). In
order to show the proof of principle that XIAP depletion
in canine cell-lines decreases the sensitivity to anti-neo-
plastic drugs, a treatment with TRAIL was used. As TRAIL
solely induces apoptosis through the extrinsic pathway,
an increase in sensitivity will show a decreased capacity of
inhibiting caspase-3 and -7. Second doxorubicin, a DNA
damaging drug which type is frequently being used for
treatment of canine tumors, was used.
Although we did not see an reduction of cell-viability in
our cell-lines when XIAP was down-regulated (data not
shown), as described by several papers [16,17], we could
demonstrate an increase in the sensitivity for different
Down-regulation of XIAP levels compared to control Figure 1
Down-regulation of XIAP levels compared to control. Relative mRNA levels from different time points from just after 
transfection up to 5 days set towards control is shown in (A). Data represent mean ± SD of six independent samples (n = 6). 
Statistically significant differences in down-regulation of XIAP mRNA at different time-points towards control were determined 
by a student t-test (*P < 0.05). Western blot analysis of immunoreactive bands of 57 kDa large XIAP protein levels after 72 
hours is shown in (B).
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Effect of XIAP loss on TRAIL sensitivity in canine cell-lines Figure 2
Effect of XIAP loss on TRAIL sensitivity in canine cell-lines. The effect on viability is shown for BDE cells in (A), for 
P114 cells in (B), and for D17 cells in (C). Control (▲ ); 50 nM XIAP siRNA (); 50 nM Nonsense siRNA (■ ). Data is repre-
sented as percentage viability towards untreated control. Points represent average of four independent experiments (n = 4). 
Statistical significance of differences in viability of the XIAP siRNA treated cell-lines at different drug concentrations compared 
to control and nonsense were determined by an one-way ANOVA using the Dunnett multiple comparisons test (*P < 0.05).
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Effect of XIAP loss on Doxorubicin sensitivity in canine cell-lines Figure 3
Effect of XIAP loss on Doxorubicin sensitivity in canine cell-lines. The effect on viability is shown for BDE cells in (A), 
for P114 cells in (B), and for D17 cells in (C). Control (▲ ); 50 nM XIAP siRNA (); 50 nM Nonsense siRNA (■ ). Data is rep-
resented as percentage viability towards untreated control. Points represent average of four independent experiments (n = 4). 
significance of differences in viability of the XIAP siRNA treated cell-lines at different drug concentrations compared to control 
and nonsense were determined by an one-way ANOVA using the Dunnett multiple comparisons test (*P < 0.05).
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Gene-expression profiles canine cell-lines Figure 4
Gene-expression profiles canine cell-lines. Quantitative mRNA measurement of IAP family members and gene-products 
involved in cellular homeostasis. Gene-expression profile of BDE-cells is shown in (A), P114-cells is shown in (B), and D17-
cells is shown in (C). Data represent mean ± SD of six independent experiments (n = 6). Statistically significant differences in 
gene-expression of different treatments towards control were determined by a student t-test (*P < 0.05).
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chemotherapeutic treatments. The fact that the introduc-
tion of XIAP siRNA's alone does not seem to reduce cell-
viability indicates a need for triggering the cells by chem-
otherapy. XIAP has been proposed as a possible treatment
of various cancers [18]. Our results showed a strong
increase in sensitivity of all three tumor cell-lines to TRAIL
treatment up to fourteen fold in XIAP siRNA treated BDE
cells. This indicates that the measured results represent a
general effect. The fact that all canine cell-lines were
increasingly sensitized through XIAP depletion holds
promises that therapeutic low concentrations TRAIL may
be effectively used without effecting somatic cells.
Doxorubicin hydrochloride, a cytotoxic anthracycline
antibiotic, is commonly used in veterinary clinical treat-
ments for various cancers [19]. However, many dog
tumors appear to be resistant to doxorubicin. In the in
vitro experiments of Macy et al. [20], five out of twenty-
one carcinomas were deemed sensitive (24 %), whereas
three out of thirteen (23 %) sarcomas showed sensitivity
to a 14 day treatment with 1 µg/ml doxorubicin. Because
of this insensitivity to high amounts of doxorubicin, a pre-
treatment with XIAP siRNA could be beneficial for many
canine tumors, lowering the concentrations needed for a
beneficial effect in sensitive tumors and could even make
insensitive tumors treatable. Although this added effect
remains to be proven in vivo, the application of siRNA's
against XIAP in combination with a chemotherapeutic
agent such as doxorubicin seems a realistic option based
on the present results. In vivo experiments with siRNA's
already have been used in various models [21-24]. In
these experiments results show that injected siRNA's are
stable and can be found in the blood for long periods,
down-regulating long half-life proteins over several days
[25]. However, the use of targeted drug-delivery systems
should still be considered for siRNA delivery [26] or
chemotherapy [27], which further enhances specificity
and potentially reduces drug-associated side-effects.
Measurements on gene expression of IAP family members
and cellular homeostasis genes did not reveal major dif-
ferences in cell-cycle progression. In the P114 cell-line,
however, the introduction of siRNA's in general seemed to
induce the cell-cycle and cellular viability. Although this
may imply an adverse effect in vivo the MTT measurements
did not reveal differences in viability of the groups (data
not shown). The IAP family members under study
(besides XIAP) did not show many significant differences
in gene-expression. In D17 cells however, a significant
increase in c-IAP1 and Smac/Diablo was seen in the non-
sense-treated cells. The effect of these differences remains
elusive, but the antagonistic properties of these proteins
could explain why little if any effect was observed in cell
viability. Taken together, some differences were seen in
cellular homeostasis or IAP family members although the
majority indicated an absence of off-target effects. How-
ever, unpublished results on TRAIL-treated cells did show
differences in gene-expression in c-IAP1. When treated for
5 hours with 50 ng/ml TRAIL, c-IAP1 induced two to
three-fold in the D17 cell-line and six to seven-fold in the
P114 cell-line, whereas no effect was seen in the BDE cells.
This indicates that the reduction in XIAP mRNA when
treated with TRAIL, could be counteracted with an
increase in c-IAP1. Furthermore, the cell-line with the
highest induction in c-IAP1 (seven-fold increase in P114)
has the least sensitivity for TRAIL treatment. This result
corroborates the hypothesis as described by Harlin et al.
where XIAP knock-out mice did not show any negative
side effects during development [10]. In this paper no
compensation due to increased gene-expression of other
family members such as c-IAP1 was seen in untreated cells
with XIAP depletion.
The use of siRNA's directed against XIAP to increase chem-
osensitivity of tumors has been described in several papers
[28-30]. Furthermore, clinical trials have started with anti-
sense oligonucleotides to treat solid tumors and hemato-
logic malignancies by Aegera pharmaceuticals (Montreal,
Canada) [31]. This study not only corroborates the found
results in these papers, the use of osteosarcoma and breast
carcinoma derived cell lines could indicate other fields of
interest. Concerns mentioned in these papers indicate the
possible role of other IAP family members after the target-
ing of XIAP[32]. As mentioned previously, in the tumor
cell lines chosen here, no compensatory effect was seen in
the IAP family members indicating a possible positive
outcome in the treatment of these tumors.
The use of spontaneously occurring tumors in companion
animals as models for human cancer has already been
described previously [14]. In this study several tumor cell
lines have been suggested as models that offer the best
comparative interest, including canine osteosarcoma and
mammary tumors. Canine mammary tumour, canine
osteosarcoma and possibly also canine hepatocellularcar-
cinoma [33] resemble human pathologies at the molecu-
lar level. Especially the first two are relatively frequently
observed in dogs. Therefore we had chosen these cell lines
as in vitro models for a-proof-of-principle. These in vitro
results provide a rational for the use of XIAP inhibition
(either with siRNA or other small molecules) in in vivo
therapies in dogs.
Conclusion
The use of XIAP siRNA to increase the sensitivity of canine
tumors for chemotherapy holds great potential. In this
study we showed an increase in sensitivity in canine cell-
lines derived from osteosarcoma, mammary carcinoma,
and cholangiocarcinoma for TRAIL and Doxorubicin
reduced cell-viability. These in vitro results provide aMolecular Cancer 2006, 5:34 http://www.molecular-cancer.com/content/5/1/34
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rational for the use of XIAP siRNA in in vivo therapeutical
use in dogs.
Methods
Cell-lines
Canine bile duct epithelial (BDE) cells were acquired
from the Amsterdam Medical Center, Experimental Liver
cell bank (Amsterdam, The Netherlands) [34]. BDE cells
were grown in DMEM (Life Technologies, Inc., Invitrogen,
Breda, The Netherlands) supplemented with 580 mg/l
glutamine, 10 µg/ml gentamicin, and 10% heat-inacti-
vated fetal bovine serum (FBS; Harlan Sera-Lab, Lough-
borough, United Kingdom) at 37°C in a humidified
atmosphere of 5% CO2 in air. P114 canine mammary
tumor cells were acquired from Dr. Rutteman from the
department of clinical sciences of companion animals,
faculty of veterinary medicine, Utrecht university, the
Netherlands. P114 cells were grown in DMEM:F12
medium (Invitrogen, Breda, The Netherlands) containing
580 mg/l glutamine, 10 µg/ml gentamicin, and 10% FBS
at 37°C in a humidified atmosphere of 5% CO2 in air
[15]. The canine osteosarcoma cells (D17) were acquired
from the American Type Culture Collection (ATCC,
Cat.no. CRL-6248) and were maintained in DMEM
medium (Invitrogen) supplemented with 580 mg/l
glutamine, 10 µg/ml gentamicin, and 10% FBS at 37°C in
a humidified atmosphere of 5% CO2 in air. For all experi-
ments cells were seeded in a concentration of 4 × 103 cells
per well in a 96-well plate 24 hours before transfection.
Establishment of the down-regulation of XIAP in canine 
tumor cell-lines
For silencing experiments, Stealth™ dsRNA molecules
were obtained from Invitrogen. A specific sequence for
canine XIAP silencing (5'-CCAUGUGCUAUACAGUCAU-
UACUUU-3') was selected after general recommendations
(Invitrogen) and was designed from the canine XIAP gene
sequence (Genbank accession no. AY603038). A non-
sense sequence was used as a negative control (5'-GCAG-
GUGCUAGUACAAGUCCGACAA-3'). Transfection was
performed with the Magnet Assisted Transfection (MATra)
technique (IBA BioTAGnology/Westburg b.v., Leusden,
The Netherlands), in combination with
lipofectamine2000™ (Invitrogen), according to the manu-
facturer's instructions. In short, 50 nM siRNA molecules
were transfected into the cell-lines in the presence of an
optimized concentration Lipofectamin2000™ (1.2 µl/ml),
for 20 minutes on the plate magnet under cell-culture
conditions. After transfection, growth media including
antibiotics replaced the transfection media. Control sam-
ples were mock transfected with lipofectamine2000™ and
magnetic beads from the MATra technique.
Treatments
For TRAIL treatment, a serial dilution of 400 to 0 ng/ml
recombinant TRAIL (R&D Systems Europe Ltd., Abing-
don, United Kingdom) was used in DMEM media (Invit-
rogen) including 10 % FCS, glutamine (580 mg/l), and
gentamycin (10 µg/ml). Treatment started 48 hours after
transfection. After a 24 hour treatment proliferation and
viability was measured with a MTT assay (5 mg/ml). For
doxorubicin treatment, a serial dilution of 100 to 0 µg/ml
doxorubicin hydrochloride (Pharmachemie b.v., Haar-
lem, The Netherlands) was used diluted in growth
medium. Treatment started 48 hours after transfection.
After 24 hour treatment proliferation and viability was
measured with a MTT assay (5 mg/ml). The experiment
was repeated four times, averages of the four independent
experiments were used in the analysis. Statistical signifi-
cance of differences in viability of the XIAP siRNA treated
cell-lines at different drug concentrations compared to
control cells were determined by an one-way ANOVA
using the Dunnett multiple comparisons test. P < 0.05 was
considered to indicate statistical significance. Analysis was
performed using SPSS software (SPSS Benelux,
Gorinchem, the Netherlands).
RNA isolation and Reverse-transcription polymerase chain 
reaction
For each group (control, XIAP siRNA, or nonsense siRNA)
the RNA of six independent experiments was isolated.
Total cellular RNA was isolated with the Qiagen RNeasy
Mini Kit according to the manufacturer's instructions
(Qiagen, Leusden, The Netherlands). In short, RNA was
isolated from each sample by adding 100 µl lysis buffer
(RLT containing 1 % (v/v) β-mercaptoethanol) directly
after decanting the media. The RNA samples were treated
with DNase-I (Qiagen RNase-free DNase kit). In total 3 µg
of RNA were incubated with poly(dT) primers at 42°C for
45 min, in a 60 µl reaction volume, using the Reverse
Transcription System from Promega (Promega Benelux,
Leiden, The Netherlands).
Quantitative measurements of the mRNA levels
Quantitative real-time PCR was performed on a total of 10
gene products; GAPDH, HPRT, XIAP, c-IAP1, c-IAP2,
Smac/Diablo, p53, caspase-3, p27kip, and CCND1. Tech-
nical triplicates were measured for each cDNA in the real-
time-PCR analysis. The abundance of mRNA was meas-
ured by real-time quantitative PCR using appropriate
primers (Table 1) as previously described [35]. In short,
Q-PCR was based on the high affinity double-stranded
DNA-binding dye SYBR® green I. For each experimental
sample, the amount of the gene of interest and of the two
independent endogenous references (glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and hypoxanthine
phosphoribosyl transferase (HPRT)) was determined
from the appropriate standard curve in autonomousMolecular Cancer 2006, 5:34 http://www.molecular-cancer.com/content/5/1/34
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experiments. If relative amounts of GAPDH and HPRT
were constant for a sample, data were considered valid
and the average amount was included in the study (data
not shown). Results were normalized according to the
average amount of the endogenous references. The nor-
malized values were divided by the normalized values of
the calibrator (healthy group) to generate relative expres-
sion levels [36]. A Kolmogorov-Smirnov test was per-
formed to establish a normal distribution and a Levene's
test for the homogeneity of variances. If samples were nor-
mally distributed, the statistical significance of differences
between diseased and control animals was determined by
using the Student's t-test. A p-value < 0.05 was considered
statistically significant. Analysis was performed using
SPSS software (SPSS Benelux, Gorinchem, the Nether-
lands).
Western blot analysis
Samples were homogenized in 350 µl RIPA buffer con-
taining 1 % Igepal, 0.6 mM Phenylmethylsulfonyl fluo-
ride, 17 µg/ml aprotinine and 1 mM sodium
orthovanadate (Sigma chemical Co., Zwijndrecht, The
Netherlands) for 30 minutes on ice. Protein concentra-
tions were obtained using a Lowry-based assay (DC Pro-
tein Assay, BioRad, Veenendaal, The Netherlands). Fifteen
µg of protein of the supernatant were denatured for 3 min
at 95°C and electroforesed on 15 % Tris-HCl polyacryla-
mide gels (BioRad) and the proteins were transferred onto
Hybond-C Extra Nitrocellulose membranes (Amersham
Biosciences Europe, Roosendaal, The Netherlands) using
a Mini Trans-Blot® Cell blot-apparatus (BioRad). The pro-
cedure for immunodetection was based on an ECL West-
ern blot analysis system, performed according to the
manufacturer's instructions (Amersham Biosciences
Europe). The membranes were incubated with 4 % ECL
blocking solution and 0.1 % Tween 20 (Boom B.V., Mep-
pel, The Netherlands) in TBS for 1 hour under gentle shak-
ing. Primary antibodies were incubated at 4°C overnight.
For XIAP a mouse anti-dog XIAP (BD Biosciences, Alphen
aan den Rijn, The Netherlands) was used in a dilution of
1:1,000 in TBST with 4% BSA. As a loading control a
mouse anti-dog Beta-Actin antibody was used in a 1:2,000
dilution in TBST with 4% BSA. After washing, the mem-
branes were incubated with a goat anti-mouse (R&D Sys-
tems/Westburg b.v.) in TBST with 4% BSA for 1 hour at
room temperature. Exposures were made with Kodak
BioMax Light-1 films (Sigma chemical Co.).
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